Maze Therapeutics(MAZE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

MAZE Maze Therapeutics

Closed 04-24 16:00:00 EDT

25.81

-0.20

-0.77%

盘后26.00

+0.19+0.74%

18:06 EDT

High25.94	Low25.10	Vol503.98K
Open25.85	D1 Closing26.01	Amplitude3.23%
Mkt Cap1.43B	Tradable Cap857.89M	Total Shares55.25M
T/O12.92M	T/O Rate1.52%	Tradable Shares33.24M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"MAZE","market":"US","secType":"STK","nameCN":"Maze Therapeutics","latestPrice":25.81,"timestamp":1777060800000,"preClose":26.01,"halted":0,"volume":503984,"hourTrading":{"tag":"盘后","latestPrice":26,"preClose":25.81,"latestTime":"18:06 EDT","volume":5493,"amount":141797.36,"timestamp":1777068383397,"change":0.19,"changeRate":0.007361,"amplitude":0.007361},"delay":0,"changeRate":-0.007689350249903992,"floatShares":33238600,"shares":55248700,"eps":-2.8431,"marketStatus":"Closed","change":-0.2,"latestTime":"04-24 16:00:00 EDT","open":25.85,"high":25.94,"low":25.1,"amount":12920516.347856,"amplitude":0.032295,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-2.8431,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1777276800000},"marketStatusCode":5,"adr":0,"listingDate":1738299600000,"exchange":"NASDAQ","adjPreClose":26.01,"preHourTrading":{"tag":"盘前","latestPrice":25.8,"preClose":26.01,"latestTime":"08:01 EDT","volume":5,"amount":127.15,"timestamp":1777032079621,"change":-0.21,"changeRate":-0.008074,"amplitude":0.011534},"postHourTrading":{"tag":"盘后","latestPrice":26,"preClose":25.81,"latestTime":"18:06 EDT","volume":5493,"amount":141797.36,"timestamp":1777068383397,"change":0.19,"changeRate":0.007361,"amplitude":0.007361},"volumeRatio":0.464418,"impliedVol":0.4176,"impliedVolPercentile":0.1184},"requestUrl":"/m/hq/s/MAZE/tweets","defaultTab":"tweets","newsList":[{"id":"2629786832","title":"Wedbush Cuts Price Target on Maze Therapeutics to $48 From $58, Keeps Outperform Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2629786832","media":"MT Newswires Live","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629786832?lang=en_us&edition=fundamental","pubTime":"2026-04-23 21:12","pubTimestamp":1776949953,"startTime":"0","endTime":"0","summary":"Maze Therapeutics (MAZE) has an average rating of buy and mean price target of $63.55, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major b","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate","earning"],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["MAZE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629076510","title":"Maze Therapeutics prices $150 million equity offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2629076510","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629076510?lang=en_us&edition=fundamental","pubTime":"2026-04-23 05:44","pubTimestamp":1776894249,"startTime":"0","endTime":"0","summary":"The latest update is out from Maze Therapeutics, Inc. ( ($MAZE) ). On April 21, 2026, Maze Therapeutics, Inc. priced an underwritten registered off...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/maze-therapeutics-prices-150-million-equity-offering?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/maze-therapeutics-prices-150-million-equity-offering?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","MAZE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629211910","title":"BUZZ-U.S. STOCKS ON THE MOVE-Tesla, AT&T, Yesway","url":"https://stock-news.laohu8.com/highlight/detail?id=2629211910","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629211910?lang=en_us&edition=fundamental","pubTime":"2026-04-23 02:01","pubTimestamp":1776880908,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Tesla, AT&T, YeswayWorkspace search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call newsletter: https://re","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260422:nL6N4150PB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BOEG","IMST","ADBE","TFX","CERT","YSWY","BA","SPWR","TEL","BOED","BSX","3LMI.UK","AMRX","MSTR","HL","BBY","NWMX","PM","DHR","MSTP","07766","T","TWLO","GEV","07799","NKTR","INBX","MAS","DGX","OTIS","CDE","HLXX","TSLS","DJT","MSTK","TH","MAZE","WAB","KYTX","HOOD","NEM","ISRG","NVR","TSLA","STX","TSLY","CALX","HLTC","COIN","RIOT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629265220","title":"BUZZ-Maze Therapeutics jumps on $150 mln share offering for kidney disease drugs","url":"https://stock-news.laohu8.com/highlight/detail?id=2629265220","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629265220?lang=en_us&edition=fundamental","pubTime":"2026-04-23 00:25","pubTimestamp":1776875120,"startTime":"0","endTime":"0","summary":"BUZZ-Maze Therapeutics jumps on $150 mln share offering for kidney disease drugs** Maze Therapeutics' MAZE.O shares up 6% to $27.23 on Weds after biopharma raises $150 mln to advance development of it","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260422:nL6N415159:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4567","BK4533","SG9999001440.SGD","BK4007","BK4207","BK4588","BK4135","TROW","MNSH","MAZE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629096481","title":"Maze Therapeutics publishes corporate presentation on genetics-driven kidney and metabolic disease pipeline","url":"https://stock-news.laohu8.com/highlight/detail?id=2629096481","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629096481?lang=en_us&edition=fundamental","pubTime":"2026-04-22 12:27","pubTimestamp":1776832062,"startTime":"0","endTime":"0","summary":"Maze outlined a kidney- and metabolic-disease pipeline built around small-molecule precision medicines, led by APOL1 inhibitor MZE829 for APOL1-mediated kidney disease .Initial Phase 2 HORIZON data showed a 36% mean reduction in uACR across 12 evaluable AMKD patients at 12 weeks.Non-diabetic AMKD patients posted a 49% mean uACR reduction, including a 62% mean reduction in FSGS subset.Safety update showed no serious adverse events in 15 treated patients; treatment-related adverse events were mostly mild or moderate.Maze projected operating capital into 2029, with additional HORIZON data targeted for late 2026 or early 2027.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Maze Therapeutics Inc. published the original content used to gener","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260422:nNDLc1SrQc:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MAZE","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629309668","title":"BRIEF-Maze Therapeutics Announces $150 Million Registered Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2629309668","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629309668?lang=en_us&edition=fundamental","pubTime":"2026-04-22 12:11","pubTimestamp":1776831060,"startTime":"0","endTime":"0","summary":"BRIEF-Maze Therapeutics Announces $150 Million Registered OfferingApril 22 (Reuters) - Maze Therapeutics Inc MAZE.O:MAZE THERAPEUTICS ANNOUNCES $150 MILLION REGISTERED OFFERINGMAZE THERAPEUTICS INC - ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260422:nTUA8CDHDM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MAZE","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629096502","title":"Maze Therapeutics prices $150 million follow-on stock offering at $23.5 per share","url":"https://stock-news.laohu8.com/highlight/detail?id=2629096502","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629096502?lang=en_us&edition=fundamental","pubTime":"2026-04-22 12:09","pubTimestamp":1776830999,"startTime":"0","endTime":"0","summary":"Maze Therapeutics priced an underwritten registered offering of 5,540,000 common shares at USD 23.5 per share.Offering also includes pre-funded warrants for up to 850,000 shares at USD 23.499 per warrant.Gross proceeds expected at about USD 150 million.Net proceeds earmarked for R&D programs including MZE829 and MZE782, with cash runway projected into 2029.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260422:nNDL2DcyZC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014039.USD","IE00BN0W2T93.GBP","IE00B3QW5Z07.USD","SG9999014005.SGD","SG9999014021.USD","LU2095319765.USD","NDAQ","BK4585","IE00BGHQF748.EUR","LU0314104364.USD","LU2210149790.SGD","BK4588","LU2210150020.SGD","SG9999014013.SGD","MNSH","BK4207","BK4007","IE00BN0W2W23.USD","IE00B64PRP62.GBP","MAZE","IE00BN0W2V16.EUR","BK4112","IE00BKPKM429.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629096503","title":"Maze Therapeutics Inc - Prices 5,540,000 Shares at $23.50 per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2629096503","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629096503?lang=en_us&edition=fundamental","pubTime":"2026-04-22 12:09","pubTimestamp":1776830984,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260422:nTUA8CDHDM:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MAZE","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627444771","title":"Maze Therapeutics Is Maintained at Buy by Truist Securities","url":"https://stock-news.laohu8.com/highlight/detail?id=2627444771","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627444771?lang=en_us&edition=fundamental","pubTime":"2026-04-14 22:03","pubTimestamp":1776175380,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/MAZE/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 14, 2026 10:03 ET (14:03 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MAZE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627448455","title":"Maze Therapeutics price target lowered to $64 from $68 at Truist","url":"https://stock-news.laohu8.com/highlight/detail?id=2627448455","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627448455?lang=en_us&edition=fundamental","pubTime":"2026-04-14 19:17","pubTimestamp":1776165468,"startTime":"0","endTime":"0","summary":"Truist lowered the firm’s price target on Maze Therapeutics (MAZE) to $64 from $68 and keeps a Buy rating on the shares. The firm has updated its o...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/maze-therapeutics-price-target-lowered-to-64-from-68-at-truist-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/maze-therapeutics-price-target-lowered-to-64-from-68-at-truist-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MAZE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627172274","title":"Analysts Offer Insights on Healthcare Companies: Travere Therapeutics (TVTX), Immuneering (IMRX) and Maze Therapeutics, Inc. (MAZE)","url":"https://stock-news.laohu8.com/highlight/detail?id=2627172274","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627172274?lang=en_us&edition=fundamental","pubTime":"2026-04-14 18:30","pubTimestamp":1776162617,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Travere Therapeutics (TVTX), Immuneering (IMRX) and ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-travere-therapeutics-tvtx-immuneering-imrx-and-maze-therapeutics-inc-maze-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-travere-therapeutics-tvtx-immuneering-imrx-and-maze-therapeutics-inc-maze-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BK4585","MAZE","TVTX","LU0128526141.USD","BK4539","BK4581","XBI","BK4007","LU0029874061.USD","HCSG","LABU","XLV","IMRX","BK4588","BK4563","BK4137"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626182292","title":"Assessing Maze Therapeutics (MAZE) Valuation After Strong One Year Return And Recent Pullbacks","url":"https://stock-news.laohu8.com/highlight/detail?id=2626182292","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626182292?lang=en_us&edition=fundamental","pubTime":"2026-04-09 19:23","pubTimestamp":1775733831,"startTime":"0","endTime":"0","summary":"Maze Therapeutics (MAZE), a clinical stage biopharma focused on kidney and metabolic diseases, has drawn investor attention after recent share price swings and a one-year total return figure that stands in sharp contrast to its recent negative short-term moves.\nSee our latest analysis for Maze Therapeutics.\nRecent trading has been choppy, with a 1 month share price return showing a 37.66% decline and a year to date share price return showing a 29.37% decline. However, the 1 year total...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-maze/maze-therapeutics/news/assessing-maze-therapeutics-maze-valuation-after-strong-one","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-maze/maze-therapeutics/news/assessing-maze-therapeutics-maze-valuation-after-strong-one","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4007","MAZE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625932021","title":"Wall Street Analysts Are Bullish on Top Healthcare Picks","url":"https://stock-news.laohu8.com/highlight/detail?id=2625932021","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625932021?lang=en_us&edition=fundamental","pubTime":"2026-04-07 19:20","pubTimestamp":1775560826,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Viridian Therapeutics (VRDN), Maze Therapeutics, Inc...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/wall-street-analysts-are-bullish-on-top-healthcare-picks-blurbs-news-93?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/wall-street-analysts-are-bullish-on-top-healthcare-picks-blurbs-news-93?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0029874061.USD","BK4585","BK4112","VRDN","XBI","MAZE","BK4581","BK4137","BLSG","BLSX","LU0128526141.USD","BK4588","LABU","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624823126","title":"Maze Therapeutics President R&D, CMO Harold Bernstein disposes shares worth $0.4 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2624823126","media":"Reuters","labels":["insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624823126?lang=en_us&edition=fundamental","pubTime":"2026-04-03 04:12","pubTimestamp":1775160750,"startTime":"0","endTime":"0","summary":"Maze Therapeutics President, R&D and CMO Harold Bernstein sold 15,000 shares on April 1.Sale prices ranged from $29.24 to $31.07 per share.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Maze Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 02, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260402:nNDL4cD845:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MAZE","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624682398","title":"Maze SVP Finance Amy Bachrodt disposes Maze Therapeutics shares worth $0.1 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2624682398","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624682398?lang=en_us&edition=fundamental","pubTime":"2026-04-03 04:11","pubTimestamp":1775160684,"startTime":"0","endTime":"0","summary":"Maze Therapeutics SVP, Finance Amy Bachrodt reported sales of 2,500 shares on April 1, 2026.Disposals totaled 2,200 shares at $29.32 per share, weighted average.Additional 300 shares were sold at $30.34 per share, weighted average.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Maze Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 02, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260402:nNDL8sVnMF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Maze SVP Finance Amy Bachrodt disposes Maze Therapeutics shares worth $0.1 million","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MAZE","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624772555","title":"Calendar of U.S. Earnings Expected in the Week Ahead","url":"https://stock-news.laohu8.com/highlight/detail?id=2624772555","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624772555?lang=en_us&edition=fundamental","pubTime":"2026-04-02 18:00","pubTimestamp":1775124000,"startTime":"0","endTime":"0","summary":"Major companies tentatively scheduled to report quarterly earnings in the week ahead, with earnings estimates provided by FactSet Research Systems Inc.·Aehr Test Sys                                   3Q      (.07)  4:05 PM. ·Delta Air Lines Inc.                             1Q       .62   6:30 AM. ·Simply Good Fds                                 2Q       .40   7:00 AM","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0310800965.SGD","LAKE","BK4149","IE00BFSS7M15.SGD","LU1235295455.SGD","IE00BJJMRX11.SGD","KRUS","GBX","LU0203345920.USD","LU0054578231.USD","LU0742537680.HKD","SG9999011175.SGD","BK4023","SMPL","LU0731783048.USD","PXED","BK4209","BK4559","LU1599440770.SGD","LU1035773651.USD","BK4500","BK4096","NEOG","IE00BKVL7J92.USD","AYI","BYRN","BK4097","LU1366192091.USD","LU0203347892.USD","LU1481011671.HKD","BK4108","AEHR","BK4167","LU0175139822.USD","BB","LU0354030511.USD","ANGO","BK4116","IE00B775H168.HKD","LU1815336091.USD","NNOX","IE0004445015.USD","BK4155","APLD","LU0052756011.USD","LU1267930227.SGD","SLP","LU0208291251.USD","SG9999003800.SGD","BK4152","LU0353189680.USD","BK4204","PSMT","BK4195","BK4212","SG9999004303.SGD","LU1481011911.USD","BK4109","RGP","IE0031619046.USD","LU2552382215.SGD","IE0005OL40V9.USD","BK4585","LU0070302665.USD","IE00BZ1G4Q59.USD","APOG","LU1983260115.SGD","LU1718418525.SGD","DAL","BK4568","LU0354030438.USD","LU1069347547.HKD","LU1430594728.SGD","IE00B66KJ199.SGD","BK4187","LU0138981039.USD","BK4588","IE00B7KXQ091.USD","LU0320765489.SGD","LU0731783394.SGD","IE00BFSS8Q28.SGD","LEVI","BK4609","IE00B19Z4B17.USD","SGXZ23171101.USD","WAFD","LU2355687059.USD","IE00B7SZL793.SGD","APLZ","LU0757428866.USD","BK4211","LU0170899867.USD","LU2552382132.HKD","LU0772969993.USD","BK4086","IE00B4JS1V06.HKD","PGR","LU2211817866.USD","LU2552382058.USD","STZ","BK4547","LU2087625088.SGD","IE0004445239.USD","LU1585245621.USD","BK4202","BK4169","LU2108987350.USD","BK4007","RPM","IE00BN29S564.USD","BK4504","LU0289960550.SGD","BK4082","IE00BFMHRM44.USD","BK4107","MAZE","LFCR","LNN","LU1509826696.USD","BK4198","BK4147","BK4563","APLX","BK4121","BK4533","BK4608","LU0128525689.USD","BK4196","BK4008","IE00BJJMRY28.SGD","BK4123"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624415549","title":"Maze Therapeutics CSBO Atul Dandekar disposes of common shares worth $0.2 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2624415549","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624415549?lang=en_us&edition=fundamental","pubTime":"2026-04-02 04:13","pubTimestamp":1775074397,"startTime":"0","endTime":"0","summary":"Maze Therapeutics CSBO Atul Dandekar sold 7,500 shares on March 30, 2026 at USD 10.42.He also sold 6,710 shares at USD 29.26.An additional 790 shares were sold at USD 30.02.Directly owned stake fell to 10,503 shares following transactions.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Maze Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 01, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260401:nNDL6Wpgm9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Maze Therapeutics CSBO Atul Dandekar disposes of common shares worth $0.2 million","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MAZE","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624530335","title":"Maze Therapeutics director Neil Kumar files initial beneficial ownership statement","url":"https://stock-news.laohu8.com/highlight/detail?id=2624530335","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624530335?lang=en_us&edition=fundamental","pubTime":"2026-04-01 04:21","pubTimestamp":1774988463,"startTime":"0","endTime":"0","summary":"Maze Therapeutics director Neil Kumar filed an initial Form 3 on March 27, 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Maze Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 31, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260331:nNDL98kVfY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MAZE","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624536287","title":"Maze Therapeutics Is Maintained at Overweight by JP Morgan","url":"https://stock-news.laohu8.com/highlight/detail?id=2624536287","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624536287?lang=en_us&edition=fundamental","pubTime":"2026-04-01 00:22","pubTimestamp":1774974120,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/MAZE/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 31, 2026 12:22 ET (16:22 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MAZE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1155589482","title":"Stock Track | Maze Therapeutics Soars 5.65% Intraday on Positive Analyst Ratings and Target Price Increases","url":"https://stock-news.laohu8.com/highlight/detail?id=1155589482","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1155589482?lang=en_us&edition=fundamental","pubTime":"2026-03-31 21:35","pubTimestamp":1774964131,"startTime":"0","endTime":"0","summary":"Maze Therapeutics' stock surged 5.65% during Tuesday's intraday trading session, reflecting strong investor interest in the biopharmaceutical company.The price movement follows a series of positive...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["MAZE"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.mazetx.com;ir.mazetx.com","stockEarnings":[{"period":"1week","weight":-0.032},{"period":"1month","weight":-0.4692},{"period":"3month","weight":-0.4125},{"period":"6month","weight":-0.1441},{"period":"1year","weight":1.7236},{"period":"ytd","weight":-0.3722}],"compareEarnings":[{"period":"1week","weight":0.0097},{"period":"1month","weight":0.0846},{"period":"3month","weight":0.0279},{"period":"6month","weight":0.0461},{"period":"1year","weight":0.3232},{"period":"ytd","weight":0.0389}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"exchange":"NASDAQ","name":"Maze Therapeutics","nameEN":"Maze Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Maze Therapeutics(MAZE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Maze Therapeutics(MAZE) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Maze Therapeutics,MAZE,Maze Therapeutics股票,Maze Therapeutics股票老虎,Maze Therapeutics股票老虎国际,Maze Therapeutics行情,Maze Therapeutics股票行情,Maze Therapeutics股价,Maze Therapeutics股市,Maze Therapeutics股票价格,Maze Therapeutics股票交易,Maze Therapeutics股票购买,Maze Therapeutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Maze Therapeutics(MAZE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Maze Therapeutics(MAZE) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction